Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 8
2005 3
2006 9
2007 7
2008 10
2009 10
2010 14
2011 31
2012 23
2013 25
2014 11
2015 17
2016 16
2017 7
2018 4
2019 3
2020 8
2021 9
2022 11
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Results by year

Filters applied: . Clear all
Page 1
Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice.
Tanaka S, Hikita H, Tatsumi T, Sakamori R, Nozaki Y, Sakane S, Shiode Y, Nakabori T, Saito Y, Hiramatsu N, Tabata K, Kawabata T, Hamasaki M, Eguchi H, Nagano H, Yoshimori T, Takehara T. Tanaka S, et al. Among authors: hiramatsu n. Hepatology. 2016 Dec;64(6):1994-2014. doi: 10.1002/hep.28820. Epub 2016 Oct 21. Hepatology. 2016. PMID: 27637015
Serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination.
Myojin Y, Hikita H, Tahata Y, Doi A, Kato S, Sasaki Y, Shirai K, Sakane S, Yamada R, Kodama T, Hagiwara H, Imai Y, Hiramatsu N, Tamura S, Yamamoto K, Ohkawa K, Hijioka T, Fukui H, Doi Y, Yamada Y, Yakushijin T, Mita E, Sakamori R, Tatsumi T, Takehara T. Myojin Y, et al. Among authors: hiramatsu n. Aliment Pharmacol Ther. 2022 Feb;55(4):422-433. doi: 10.1111/apt.16691. Epub 2021 Nov 23. Aliment Pharmacol Ther. 2022. PMID: 34812502 Clinical Trial.
Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral.
Matsumae T, Kodama T, Tahata Y, Myojin Y, Doi A, Nishio A, Yamada R, Nozaki Y, Oshita M, Hiramatsu N, Morishita N, Ohkawa K, Hijioka T, Sakakibara M, Doi Y, Kakita N, Yakushijin T, Sakamori R, Hikita H, Tatsumi T, Takehara T. Matsumae T, et al. Among authors: hiramatsu n. Cancers (Basel). 2023 Jan 11;15(2):463. doi: 10.3390/cancers15020463. Cancers (Basel). 2023. PMID: 36672412 Free PMC article.
Percutaneous transhepatic endoscopic necrosectomy for infected hepatic necrosis.
Kurahashi T, Ohnishi K, Yoneda N, Tanimoto T, Hirao M, Yamada T, Hosui A, Hiramatsu N. Kurahashi T, et al. Among authors: hiramatsu n. Gastrointest Endosc. 2023 Nov;98(5):864-865. doi: 10.1016/j.gie.2023.06.042. Epub 2023 Jun 27. Gastrointest Endosc. 2023. PMID: 37379997 No abstract available.
Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Maesaka K, Sakamori R, Yamada R, Doi A, Tahata Y, Ohkawa K, Oshita M, Miyazaki M, Yakushijin T, Nozaki Y, Matsumoto K, Tanaka S, Kaneko A, Iio S, Nawa T, Yamada Y, Morishita N, Usui T, Hiramatsu N, Doi Y, Sakakibara M, Imanaka K, Yoshida Y, Kodama T, Hikita H, Tatsumi T, Takehara T. Maesaka K, et al. Among authors: hiramatsu n. PLoS One. 2023 Feb 7;18(2):e0281459. doi: 10.1371/journal.pone.0281459. eCollection 2023. PLoS One. 2023. PMID: 36749777 Free PMC article.
Reducing relapse through maintenance steroid treatment can decrease the cancer risk in patients with IgG4-sclerosing cholangitis: Based on a Japanese nationwide study.
Kubota K, Kamisawa T, Nakazawa T, Tanaka A, Naitoh I, Kurita Y, Takikawa H, Unno M, Kawa S, Masamune A, Nakamura S, Okazaki K; Collaborators. Kubota K, et al. J Gastroenterol Hepatol. 2023 Apr;38(4):556-564. doi: 10.1111/jgh.16066. Epub 2023 Jan 10. J Gastroenterol Hepatol. 2023. PMID: 36403136
Solitary fibrous tumor of the liver from development to resection.
Makino Y, Miyazaki M, Shigekawa M, Ezaki H, Sakamori R, Yakushijin T, Ohkawa K, Kato M, Akasaka T, Shinzaki S, Nishida T, Miyake Y, Hama N, Nagano H, Honma K, Morii E, Wakasa K, Hikita H, Tatsumi T, Iijima H, Hiramatsu N, Tsujii M, Takehara T. Makino Y, et al. Among authors: hiramatsu n. Intern Med. 2015;54(7):765-70. doi: 10.2169/internalmedicine.54.3053. Epub 2015 Apr 1. Intern Med. 2015. PMID: 25832939 Free article. Review.
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study.
Kai M, Hikita H, Kazuki M, Tahata Y, Shinkai K, Doi A, Ohkawa K, Miyazaki M, Ishida H, Matsumoto K, Nozaki Y, Yakushijin T, Sakamori R, Kaneko A, Iio S, Nawa T, Kakita N, Morishita N, Hiramatsu N, Usui T, Imanaka K, Doi Y, Sakakibara M, Yoshida Y, Oze T, Kodama T, Tatsumi T, Takehara T. Kai M, et al. Among authors: hiramatsu n. PLoS One. 2024 Jan 2;19(1):e0294590. doi: 10.1371/journal.pone.0294590. eCollection 2024. PLoS One. 2024. PMID: 38165900 Free PMC article.
195 results